Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

Pharmacogenetics

Volumn 14, Issue 8, 2004, Pages 539-547

  Hillman, Michael A ^a   Wilke, Russell A ^a   Caldwell, Michael D ^a   Berg, Richard L ^a   Glurich, Ingrid ^a   Burmester, James K ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Age; Anticoagulation therapy; Coumadin maintenance dose; Cytochrome P450 2C9; Diabetes mellitus; INR; Personalized medicine; Pharmacogenomics; Prosthetic heart valve; Warfarin

Indexed keywords

AMIODARONE; AMITRIPTYLINE; CANDESARTAN; CARBAMAZEPINE; CELECOXIB; CIMETIDINE; CLONAZEPAM; COTRIMOXAZOLE; CYTOCHROME P450 2C9; ESOMEPRAZOLE; FLUCONAZOLE; FLUINDOSTATIN; FLUOXETINE; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; IBUPROFEN; IMIPRAMINE; IRBESARTAN; LOSARTAN; METRONIDAZOLE; MONTELUKAST; NAPROXEN; OMEPRAZOLE; ROFECOXIB; SERTRALINE; SULFONAMIDE; UNINDEXED DRUG; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BODY SURFACE; CAUCASIAN; COHORT ANALYSIS; COMORBIDITY; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENOTYPE; HEART ATRIUM ARRHYTHMIA; HEART VALVE REPLACEMENT; HUMAN; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MULTIPLE REGRESSION; PRESCRIPTION; PRIORITY JOURNAL;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DRUG INTERACTIONS; DRUG RESISTANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HEART VALVES; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; WARFARIN;

EID: 4143065736     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000114760.08559.dc     Document Type: Article

References (83)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
2. Burke W. Genetic testing. N Engl J Med 2002; 347:1867-1875.
3. Couzin J. Genomics, New mapping project splits the community. Science 2002; 296:1391-1393.
4. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003; 348:553-556.
5. Gura T. Genetics. SNP-ing drugs to size. Science 2001; 293:595.
6. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921.
7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-1205.
8. Rothberg BE. Mapping a role for SNPs in drug development. Nature Biotechnol 2001; 19:209-211.
9. Schork NJ, Fallin D, Thiel B, Xu X, Broeckel U, Jacob HJ, et al. The future of genetic case-control studies. Adv Genet 2001; 42:191-212.
10. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7:201-204.
11. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291:1304-1351.
12. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537.
13. Lipton P. Pharmacogenetics: the ethical issues. Pharmacogenomics J 2003; 3:14-16.
14. Cundiff DK. Anticoagulants for nonvalvular atrial fibrillation (NVAF) - drug review. Med Gen Med 2003; 5:4 [http//www.medscape.com/viewarticle/448817].
15. Bader JS. The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2001; 2:11-24.
16. Judson R, Stephens JC. Notes from the SNP versus haplotype front. Pharmacogenomics 2001; 2:7-10.
17. O'Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics 2003; 4:1-4.
18. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis 2002; 22:123-136.
19. Pauli-Magnus C, Meier PJ. Pharmacogenetics of hepatocellular transporters. Pharmacogenetics 2003; 13:189-198.
20. Iqbal O. Pharmacogenomics in anticoagulant drug development. Pharmacogenomics 2002; 3:823-828.
21. Humpert PM, Isermann B, Rudofsky G, Ziegler R, Bierhaus A, Ritz E, et al. The 20210 G to A prothrombin polymorphism and late complications in type 1 diabetes mellitus. Thromb Haemost 1999; 81:164.
22. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997; 78:1430-1433.
23. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89:2817-2821.
24. Siscovick DS, Schwartz SM, Rosendaal FR, Psaty Biol. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost 1997; 78:7-12.
25. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96:412-417.
26. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90:1747-1750.
27. Longstreth WT Jr, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29:577-580.
28. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT Jr, Pearce RM, Rosendaal FR, et al. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000; 31:1628-1633.
29. Frank MB, Reiner AP, Schwartz SM, Kumar PN, Pearce RM, Arbogast PG, et al. The Kozak sequence polymorphism of platelet glycoprotein Ibalpha and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood 2001; 97:875-879.
30. Reiner AP, Schwartz SM, Kumar PN, Rosendaal FR, Pearce RM, Aramaki KM, et al. Platelet glycoprotein IIb polymorphism, traditional risk factors and non-fatal myocardial infarction in young women. Br J Haematol 2001; 112:632-636.
31. Reiner AP, Schwartz SM, Frank MB, Longstreth WT Jr, Hindorff LA, Teramura G, et al. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke 2001; 32:2580-2586.
32. Reiner AP, Frank MB, Schwartz SM, Linenberger ML, Longstreth WT, Teramura G, et al. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol 2002; 116:376-382.
33. Davis NB, Nahlik L, Vogelzang NJ. Does PC-SPEs interact with warfarin? J Urol 2002; 167:1793.
34. Ageno W, Turpie AG. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol 1999; 84:905-908.
35. Roberts GW, Helboe T, Nielsen CB, Gallus AS, Jensen I, Cosh DG, et al. Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother 2003; 37:799-803.
36. Demirkan K, Stephens MA, Newman KP, Self TH. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 2000; 93:448-455.
37. Dunn AS, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks HS, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001; 110:458-462.
38. Keene ON. The log transformation is special. Stat Med 1995; 14:811-819.
39. Finn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124:970-979.
40. Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002; 36:200-204.
41. Rosenbaum CC, Woods SE, Hasselfeld KA. Correlation of the change in the International Normalized Ratio and decreasing the Coumadin dosage following total joint arthroplasty. Orthopedics 2002; 25:1359-1363.
42. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 2001; 70:159-164.
43. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698.
44. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361-387.
45. Thall PF, Lachin JM. Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. Stat Med 1986; 5:73-83.
46. Belsley DA, Kuh E, Welsch RE. Regression Diagnostics. New York: John Wiley and Sons, Inc.; 1980.
47. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-719.
48. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. Br J Clin Pharmacol 2002; 53:408-409.
49. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254:628-631.
50. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6:429-439.
51. Schork NJ. Power calculations for genetic association studies using estimated probability distributions. Am J Hum Genet 2002; 70:1480-1489.
52. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.
53. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7:203-210.
54. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333:447-458.
55. Doecke CJ, Cosh DG, Gallus AS. Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response. Aust NZJ Med 1991; 21:319-324.
56. Wynne HA, Kamali F, Edwards C, Long A, Kelly P. Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing 1996; 25:429-431.
57. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. Eur J Clin Pharmacol 1979; 15:319-322.
58. Anonymous. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687-691.
59. Wintzen AR, de Jonge H, Loeliger EA, Bots GT. The risk of intracerebral hemorrhage during oral anticoagulation treatment: a population study. Ann Neurol 1984; 16:553-558.
60. Desbiens NA. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis. J Am Geriatr Soc 2002; 50:863-869.
61. Kamath S, Lip GY. Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly. Am J Geriatr Cardiol 2002; 11:357-364.
62. Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000; 29:31-34.
63. Engova D, Duggan C, Shearer M, Cotter F, MacCallum P. Effects of age and cytochrome P450 polymorphism on the maintenance dose of warfarin. Blood 2002; 100:502A-503A.
64. Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003; 120:526-528.
65. Brenner SS, Herrlinger C, Dilger K, Murdter TE, Hofmann U, Marx C, et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42:283-292.
66. Anonymous. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996; 156:409-416.
67. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72:326-332.
68. Kim KY, Mancano MA. Fenofibrate potentiates warfarin effects. Ann Pharmacother 2003; 37:212-215.
69. Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, et al. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther 2002; 71:496-502.
70. Adams JN, Gautam PC. Anticoagulant therapy in elderly patients. J Clin Exp Gerontol 1992; 14:183-196.
71. Wickramasinghe LS, Basu SK, Bansal SK. Long-term oral anticoagulant therapy in elderly patients. Age Ageing 1988; 17:388-396.
72. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349:675-683.
73. Kelly KC, Raj G, Weideman RA. Influence of body weight on response to subcutaneous vitamin K administration in over-anticoagulated patients. Am J Med 2001; 110:623-627.
74. Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2000; 172:600-605.
75. Knobl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R, et al. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36:1045-1050.
76. Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21:152-160.
77. Ruiz J. Diabetes mellitus and the late complications: influence of the genetic factors. Diabetes Metab 1997; 23:57-63.
78. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18:84-112.
79. Lehmann DE. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. Pharmacotherapy 2000; 20:1464-1468.
80. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003; 424:464-468.
81. Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349:343-349.
82. Wadelius M, Sörlin K, Wallerman O, Karlsson J, Yue Q-Y, Magnusson PKE, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2003; 3:1-9.
83. van Aken J, Schmedders M, Feuerstein G, Kollek R. Prospects and limits of pharmacogenetics. The thiopurine methyl transferase (TPMT) experience. Am J Pharmacogenomics 2003; 3:149-155.